Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Carboplatin, and Gemcitabine in Ovarian Cancer
NCT00031954Phase 2Completed
- Sponsor
- AGO Study Group
- Start
- Aug 2001
- Primary completion
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by AGO Study Group. Primary endpoints: Tolerability and Toxicity and Drop-out Rate Due to Toxicity. Started Aug 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00031954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031954.